NASDAQ:FGEN - FibroGen Stock Price, News & Analysis

$41.42
-0.40 (-0.96 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$40.68
Now: $41.42
$41.77
50-Day Range
$40.81
MA: $44.34
$48.34
52-Week Range
$33.51
Now: $41.42
$61.95
Volume25,183 shs
Average Volume523,118 shs
Market Capitalization$3.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.87
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$212.96 million
Book Value$6.22 per share

Profitability

Net Income$-86,420,000.00

Miscellaneous

Employees461
Market Cap$3.60 billion
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.


FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) announced its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $1.75. The biopharmaceutical company had revenue of $191.57 million for the quarter, compared to the consensus estimate of $29.03 million. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The company's revenue for the quarter was up 335.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

7 Wall Street analysts have issued 12 month price objectives for FibroGen's shares. Their predictions range from $40.00 to $84.00. On average, they expect FibroGen's stock price to reach $62.6667 in the next twelve months. This suggests a possible upside of 51.3% from the stock's current price. View Analyst Price Targets for FibroGen.

What is the consensus analysts' recommendation for FibroGen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.

Has FibroGen been receiving favorable news coverage?

News articles about FGEN stock have trended negative on Tuesday, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. FibroGen earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for FibroGen.

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Transocean (RIG).

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
  • Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 57)
  • Mr. Julian N. Stern, Sec. (Age 94)
  • Dr. Barry A. Berkowitz, Founder

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.45%), BlackRock Inc. (7.23%), BlackRock Inc. (7.17%), Hillhouse Capital Advisors LTD. (3.13%), Janus Henderson Group PLC (2.90%) and Janus Henderson Group PLC (2.90%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Gerald Lema, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Which major investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Candriam Luxembourg S.C.A., Morgan Stanley, Price T Rowe Associates Inc. MD, Bank of America Corp DE, UBS Asset Management Americas Inc., Handelsbanken Fonder AB and Pinnacle Associates Ltd.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz and Thomas B Neff. View Insider Buying and Selling for FibroGen.

Which major investors are buying FibroGen stock?

FGEN stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Hillhouse Capital Advisors LTD., JPMorgan Chase & Co., Nuveen Asset Management LLC, Westfield Capital Management Co. LP, Invesco Ltd., Janus Henderson Group PLC and Janus Henderson Group PLC. View Insider Buying and Selling for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $41.42.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.60 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. FibroGen employs 461 workers across the globe.View Additional Information About FibroGen.

What is FibroGen's official website?

The official website for FibroGen is http://www.fibrogen.com/.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]


MarketBeat Community Rating for FibroGen (NASDAQ FGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  528
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel